Physician profile
Nancy Taylor
NPI 1295916765
$1,578.22
in general payments reported to CMS, 2019-2025
26 companies · $564 in 2025
The $564 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.83 · 2022: $44.55 · 2023: $439 · 2024: $518 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.85 |
| Education | $162.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $272.32 | 2022-2025 | Zynyz, Monjuvi, Jakafi |
| Pfizer INC. | $140.42 | 2024-2025 | |
| Janssen Biotech, INC. | $136.55 | 2023-2025 | Erleada, Akeega, Balversa |
| Novartis Pharmaceuticals Corporation | $128.88 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.74 | 2023-2024 | Lynparza, Enhertu |
| Sobi, INC | $98.55 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $71.89 | 2024 | Keytruda, Lynparza |
| Genzyme Corporation | $71.78 | 2023-2024 | |
| Celgene Corporation | $67.52 | 2023 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $58.72 | 2023-2024 | Enhertu |
| Glaxosmithkline, LLC. | $44.77 | 2024-2025 | Ojjaara |
| Agios Pharmaceuticals, INC. | $34.97 | 2024-2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $31.80 | 2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $30.83 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Exelixis INC. | $29.93 | 2025 | Cabometyx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $28.49 | 2023 | Epkinly |
| Pharmacosmos Therapeutics INC. | $27.35 | 2023 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $26.69 | 2025 | Fruzaqla |
| Fresenius Kabi USA, LLC | $26.48 | 2024 | Stimufend |
| Lilly USA, LLC | $24.93 | 2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $24.91 | 2023 | |
| Stemline Therapeutics INC. | $24.11 | 2024 | Orserdu |
| Blueprint Medicines Corporation | $20.79 | 2024 | Ayvakit |
| Kite Pharma, INC. | $19.85 | 2023 | |
| Amgen INC. | $13.12 | 2023 | Lumakras |
| Kyowa Kirin, INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.